SCHEMBL969465

SCHEMBL969465

Sc1nnc(-c2csnn2)s1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.38
RAB9A P51151 3/20 0.38
MEN1 O00255 2/20 0.38
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 2/20 0.38
NOTUM Q6P988 1/20 0.38
LMNA P02545 1/20 0.36
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MAPT P10636 1/20 0.33
CDC25A P30304 1/20 0.31
CDC25B P30305 1/20 0.31
CDC25C P30307 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1624105 0.71 KMT2A (0.54) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL969140 0.69 IDO1 (0.36) RAB9ANPC1SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL10435185 0.67 KDM4E (0.38) RAB9ANPC1SMN1; SMN2POLBALDH1A1
SCHEMBL14557099 0.66 KDM4E (0.43) RAB9ANPC1SMN1; SMN2POLBNOTUM
SCHEMBL4073593 0.65 RAB9A (0.41) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL971007 0.64 KDM4E (0.74) RAB9ANPC1SMN1; SMN2POLBLMNA
SCHEMBL969939 0.64 KDM4E (0.59) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL10510933 0.64 KMT2A (0.39) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL19900671 0.62 KMT2A (0.78) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL11436591 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
EP-1970377-A1 LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 KMT2A 2133/4885RAB9A 377/4885MEN1 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.